CDK4 and breast cancer: Interestingly, many ongoing trials are evaluating the continuation of CDK4/6 inhibition beyond progression in advanced ER+, HER2− BC: MAINTAIN (NCT02632045), NCT02871791, TRINITI-1 (NCT02732119), PACE (NCT03147287), and NCT01857193.